NCT06338397 Social & Affective Cognition in Alzheimer's Disease & Associated Disorders
| NCT ID | NCT06338397 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Lille |
| Condition | Alzheimer's Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-01-28 |
| Primary Completion | 2028-01-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2025-01-28 with a primary completion date of 2028-01-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Recent studies have shown that individual neuropsychological scores of patients with Alzheimer's disease and Associated Disorders (ADAD) are only poorly correlated to their behavioral difficulties, such as disinhibition, apathy, social decision-making or vulnerability. Recently, social \& affective cognitive disorders have been highlighted as potential cause of social behavioral abnormalities. However, no previous studies have assessed the specific relationship between social \& affective cognition \& social behavior in ADAD. Our pilot study aims to explore the correlations between core and extended social \& affective cognitive processes and social behavior as observed during the neuropsychological examination, as well as to explore the common brain regions involved in those domains.
Eligibility Criteria
Inclusion Criteria: * Men and women; * 40 to 85 years of age (included); * Registered with the French Social Security; * Have a study partner. The study partner is required to complete several scales. If the subjects or their study partners are not able to drive, their transport fees will be reimbursed by the promotor. * Fluent in French, able to read and write; Exclusion Criteria: * Participants who have contraindications to perform an MRI scan; * Participants with significant sensory deficits that are not corrected by suitable devices. * Participants with dementia caused by a non-neurodegenerative disease, including patients with severe cerebrovascular risk factor load, in the judgment of the investigator; * Participants with other neurodegenerative disease such as Lewy body dementia and Parkinson's disease; * Participants with other serious neurological disorder such as brain tumor, stroke, epilepsy, hydrocephalus and any condition which contraindicates, in the investigator's judgment, entry to the study; * Participants with excessive alcohol intake or drug abuse, in the judgment of the investigator; * Participants who, in the opinion of the investigator, have a risk of non-compliance to the study procedures;
Contact & Investigator
Thibaud LEBOUVIER, MD, PhD
PRINCIPAL INVESTIGATOR
University Hospital, Lille
Frequently Asked Questions
Who can join the NCT06338397 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 85 Years, studying Alzheimer's Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06338397 currently recruiting?
Yes, NCT06338397 is actively recruiting participants. Contact the research team at Thibaud.LEBOUVIER@chu-lille.fr for enrollment information.
Where is the NCT06338397 trial being conducted?
This trial is being conducted at Lille, France.
Who is sponsoring the NCT06338397 clinical trial?
NCT06338397 is sponsored by University Hospital, Lille. The principal investigator is Thibaud LEBOUVIER, MD, PhD at University Hospital, Lille. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.